FCX News 38.06 07/29/2014 05:05:17 Freeport-Mcmoran Copper &

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Freeport-Mcmoran Copper & Gold (FCX) 38.06 $FCX

'Fast Money' Recap: Playing China Through U.S. Stocks
at The Street - 1 hr 4 mins ago
The trading panel looked at the Shanghai composite index and how investors can use U.S. stocks as a proxy.

Freeport (FCX) to Resume Exports from Indonesian Subsidiary - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 5:25PM CDT
Freeport-McMoRan Inc. (FCX) has signed a Memorandum of Understanding (MOU) with the Government of Indonesia which has granted it the approval to resume operations at its Indonesian subsidiary PT Freeport Indonesia (PT-FI).

Freeport-McMoRan’s Oil and Gas Transformation Isn’t Over Just Yet
Matt DiLallo, The Motley Fool - Motley Fool - Mon Jul 28, 12:36PM CDT
Freeport-McMoRan spent much of last quarter repositioning the oil and gas business it bought last year. Not only did the company cash in its chips in the Eagle Ford Shale, but it took that money and increased its bet on the Gulf of Mexico. It did...

Why Investors Shrugged Off Freeport-McMoRan's Earnings Miss
Matt DiLallo, The Motley Fool - Motley Fool - Fri Jul 25, 11:10AM CDT
Source: Anadarko Petroleum.  When Freeport-McMoRan missed earnings estimates by $0.03 a share , I thought investors would sell off the stock. Surprisingly, that didn't happen, as investors wisely saw through the miss for what it was. Which, in...

Freeport-McMoRan Announces Resumption of Exports from Indonesian Subsidiary
Business Wire - Fri Jul 25, 9:28AM CDT
Freeport-McMoRan Inc. (NYSE: FCX) announced today that its Indonesian subsidiary PT Freeport Indonesia (PT-FI) received approval from the Government of Indonesia to resume exports of copper concentrates. PT-FI will resume full operations immediately and concentrate exports are expected to commence in August 2014.

Freeport-McMoRan Has Returned 14.2% Since SmarTrend Recommendation (FCX)
Comtex SmarTrend(R) - Thu Jul 24, 4:52PM CDT
SmarTrend identified an Uptrend for Freeport-McMoRan (NYSE:FCX) on March 28th, 2014 at $32.87. In approximately 4 months, Freeport-McMoRan has returned 14.18% as of today's recent price of $37.53.

SmarTrend Watching for Potential Rebound in Shares of Freeport-McMoRan After 2.65% Loss
Comtex SmarTrend(R) - Thu Jul 24, 3:41PM CDT
Freeport-McMoRan (NYSE:FCX) traded in a range yesterday that spanned from a low of $37.30 to a high of $38.14. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $38.27 on volume of 15.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

After Yesterday's Decline of 2.65%, Freeport-McMoRan Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jul 24, 3:40PM CDT
Freeport-McMoRan (NYSE:FCX) traded in a range yesterday that spanned from a low of $37.30 to a high of $38.14. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $38.27 on volume of 15.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Is Noble Corp's Plunge an Opportunity for Dividend Investors?
Daniel Gibbs, The Motley Fool - Motley Fool - Thu Jul 24, 1:48PM CDT
Several offshore drilling companies have seen their stock prices decline from the levels that they traded at a year ago. The reason for this is that the industry is suffering from a temporary slowdown due to oil and gas companies putting less rigs...

Why Freeport-McMoRan (FCX) Stock Is Declining Today
at The Street - Thu Jul 24, 1:08PM CDT
Freeport-McMoRan (FCX) shares are down after being downgraded to 'neutral' by analysts at Bank of America/Merrill Lynch (BAC).

1 Crucial Fact Investors Must Know About ConocoPhillips
Aimee Duffy, The Motley Fool - Motley Fool - Thu Jul 24, 12:32PM CDT
I'm not a petroleum engineer, and most likely neither are you. Too bad, because if we were, our services would really be in demand right now . The oil and gas industry is clamoring to attract -- and keep -- top talent. As they battle it out for the...

Will Freeport-McMoRan (FCX) Stock Be Hurt By This Ratings Downgrade?
at The Street - Thu Jul 24, 8:10AM CDT
Freeport-McMoRan (FCX) was downgraded to 'neutral' from 'buy' at Bank of America/Merrill Lynch (BAC).

Freeport-McMoRan announces unchanged net income of USD482m for Q2 2014
M2 - Thu Jul 24, 6:26AM CDT
Natural resource company Freeport-McMoRan (NYSE:FCX) on Wednesday declared net income attributable to common stock of USD482m (USD0.46 per share) for the second-quarter 2014,

No Breakthrough Yet in Indonesian Mining Logjam
Rich Duprey, The Motley Fool - Motley Fool - Wed Jul 23, 3:20PM CDT
Continuing to hold miners hostage to its demands they pay a king's ransom for the right to ship unprocessed ore out of the country, Indonesia announced late last week that two companies agreed to pay the tax it imposed and were allowed to export...

Will Freeport-McMoran (FRCX) Stock Be Helped By Expanded Asset Sale?
at The Street - Wed Jul 23, 2:59PM CDT
Freeport-McMoran (FCX) will expand sales of onshore assets to reduce debt as it focuses on deep-water oil and natural gas finds in the Gulf of Mexico.

Freeport's (FCX) Q2 Earnings, Revs Top Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 23, 12:08PM CDT
Freeport-McMoRan Copper & Gold Inc.'s (FCX) earnings were 58 cents a share (excluding one-time items) in the second quarter 2014, topping the Zacks Consensus Estimate of 49 cents.

Freeport-McMoRan Inc. Misses as Indonesian Copper Exports Remain Delayed
Matt DiLallo, The Motley Fool - Motley Fool - Wed Jul 23, 8:47AM CDT
Freeport-McMoRan announced second-quarter results before the market opened this morning. The global resources company reported revenue of $5.52 billion and net income of $482 million, or $0.46 per share. While revenue beat estimates by $280...

Freeport-McMoRan Reports Second-Quarter and Six-Month 2014 Results
Business Wire - Wed Jul 23, 7:01AM CDT
Freeport-McMoRan Inc. (NYSE: FCX):

Freeport-McMoRan (FCX) Breaks Through Resistance at $38.86
Comtex SmarTrend(R) - Tue Jul 22, 12:28PM CDT
Shares of Freeport-McMoRan (NYSE:FCX) have bullishly opened above the pivot of $38.56 today and have reached the first resistance level of $38.86. Analysts will be watching for a cross of the next upside pivot targets of $39.04 and $39.52.

What to Watch When Freeport-McMoRan Reports
Matt DiLallo, The Motley Fool - Motley Fool - Tue Jul 22, 10:45AM CDT
Photo credit: Flickr/ Jim Sneddon   Freeport-McMoRan is expected to report its second-quarter results on Wednesday. The global resources company is expected to report $5.24 billion in revenue and earnings of $0.49 per share. If Freeport-McMoRan...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 170

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 336

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 372

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 64

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Trump's Executive Orders and Their Economic Impact

Updated Category News Views 806

Executive Orders: A Shift in Economic Paradigms President Trump has taken significant steps by issuing a number of executive orders that have raised eyebrows among economists and market analysts alike. According to market expert Louis Navellier, this approach can be characterized as 'shock and awe'. It reflects a bold strategy that could reshape various aspects of the...

Continue Reading
B2PRIME Expands Institutional Reach with Stuart Brock's Addition

Updated Category News Views 173

B2PRIME Welcomes Stuart Brock as Institutional Business Development Manager B2PRIME Group, a leading financial services provider for institutional and professional clients, recently announced the appointment of Stuart Brock as its Institutional Business Development Manager. With over 15 years of experience in electronic trading and institutional sales, Stuart is poised to...

Continue Reading
United Parks & Resorts Inc. Shares Q1 2025 Financial Insights

Updated Category News Views 374

Financial Overview of United Parks & Resorts Inc. United Parks & Resorts Inc. (NYSE: PRKS), a prominent player in the theme park and entertainment sector, has recently shared its financial results for the first quarter of 2025. This report delves into the key metrics and operational insights that define the company’s performance in this period. Attendance and Revenue...

Continue Reading
Seongnam Pavilion Sets New Benchmark at CES 2025 with 41 Companies

Updated Category News Views 178

Seongnam Pavilion Makes Waves at CES 2025 At the latest CES 2025, Seongnam City showcased an impressive turnout at the world's leading consumer electronics exhibition. This year, Seongnam participated with a remarkable delegation of 41 companies, marking the largest participation ever. Focused on enhancing their global footprint, these small and medium-sized enterprises...

Continue Reading
Gaucho Holdings Seizes Opportunities Amid Argentina's Economic Revival

Updated Category News Views 179

Gaucho Holdings and the New Economic Landscape in Argentina Recently, Argentina has entered a new chapter of economic transformation. A shift in leadership, with Javier Milei becoming president, has sparked hopes for fiscal discipline, growth, and development. As the country embraces pro-market reforms, Gaucho Group Holdings, Inc. (NASDAQ: VINO) positions itself to...

Continue Reading